Supernus Pharmaceuticals (SUPN) said Tuesday that the US Food and Drug Administration has approved its Onapgo injection to treat motor fluctuations in adults with advanced Parkinson's disease.
The biopharmaceutical company said Onapgo will be available in Q2.
Shares of Supernus Pharmaceuticals were up more than 4% in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.